Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2481-2490 Newer>

The Motley Fool November 1, 2005 Stephen D. Simpson	Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment.
Managed Care October 2005 MargaretAnn Cross	Just How Will CDHC Change Your Job? Medical directors are charged with many of the tasks that could help members make the most of consumer-directed health plans.
Managed Care October 2005 Bob Carlson	What Docs Hate Most About Plans Some insurers seem to have a knack for irritating their network physicians. The list is long, but five categories of irritants seem to recur most often.
Managed Care October 2005 Michael S. Victoroff	What Katrina Teaches Us About Rules & Structures A defining canon of managed care is "Getting the right treatment to the right person at the right time." Katrina demonstrated how fragile this proposition is under conditions of extreme social disorganization.
Managed Care October 2005 Martin Sipkoff	Restrictive Formularies May Be Contagious It's the law of unintended consequences: A restrictive drug formulary maintained by a health plan may influence how physicians treat patients unaffiliated with that plan. What does this mean to managed care?
Managed Care October 2005	Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution.
BusinessWeek November 7, 2005 Lorraine Woellert	A Break For The Defense As doctors who validate tort claims come under scrutiny, business is on the offensive.
The Motley Fool October 31, 2005 Brian Gorman	Charles River Labs' Seesaw The company is balancing softness in its research models with strength in preclinical services. A wait-and-see attitude toward the stock may be appropriate due to weakness in research models and the company's ambitious expansion plans.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool October 31, 2005 Charly Travers	A Myriad of Shares Management's predilection for excessive share dilution at Myriad Genetics is troubling for investors.
<Older 2481-2490 Newer> Return to current articles.